← Back to Search

Antiviral

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1), day 3, day 10 and day 14

Summary

This trial is testing a new medicine called PF-07817883 to see if it can lower the amount of COVID-19 virus in adults who have symptoms but are not hospitalized. The goal is to help these people recover faster by reducing the virus levels in their bodies.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1), day 3, day 10 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1), day 3, day 10 and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5
Secondary study objectives
Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14
Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities
Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities
+3 more

Side effects data

From 2023 Phase 2 trial • 240 Patients • NCT05799495
3%
Alanine aminotransferase increased
3%
Supraventricular extrasystoles
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
PF-07817883 300mg
PF-07817883 600mg
PF-07817883 100mg

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 3: high doseExperimental Treatment1 Intervention
Group II: Arm 2: medium doseExperimental Treatment1 Intervention
Group III: Arm 1: low doseExperimental Treatment1 Intervention
Group IV: Arm 4: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07817883
2022
Completed Phase 2
~370

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,669 Previous Clinical Trials
17,861,684 Total Patients Enrolled
73 Trials studying COVID-19
4,913,665 Patients Enrolled for COVID-19
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,553 Previous Clinical Trials
14,902,686 Total Patients Enrolled
56 Trials studying COVID-19
4,902,536 Patients Enrolled for COVID-19

Media Library

PF-07817883 (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT05799495 — Phase 2
COVID-19 Research Study Groups: Arm 3: high dose, Arm 4: Placebo, Arm 1: low dose, Arm 2: medium dose
COVID-19 Clinical Trial 2023: PF-07817883 Highlights & Side Effects. Trial Name: NCT05799495 — Phase 2
PF-07817883 (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05799495 — Phase 2
~96 spots leftby Dec 2025